CAR-T cell therapy autoimmune disease trials at ACR Convergence 2026 showed drug-free remissions in treatment-resistant lupus ...

Six patients treated: three show strong responses, three not so much ...

A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with ...

A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with ...

An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

CAR-T cell therapy has transformed the treatment of many blood cancers since it was first approved by the Food and Drug Administration in 2017 for the treatment of acute lymphoblastic leukemia. But ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

CAR T-cell therapy modifies a patient's immune cells to target cancer, offering potential cures for blood cancers like lymphoma and myeloma. Up to 40% of lymphoma patients may achieve remission after ...

From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...

That is how hematologist-oncologist and Stanford Cancer Institute member Melody Smith, MD, describes CAR-T cell therapy to her patients, a simple metaphor for a treatment that is changing the way ...